Lexology January 8, 2025
In the post-Dobbs landscape, there has been a renewed focus on medication abortion as an option for expanding access to abortion care for people residing in states with abortion bans or restrictions. Given the increased availability of medication abortion throughout the U.S. via telemedicine, this area has attracted several legal challenges that could create exposure and compliance risk for managed care organizations (MCOs).
The two-drug combination of mifepristone and misoprostol is the most common medication abortion regimen in the U.S. and can be safely used until up to 10 weeks of pregnancy according to the U.S. Food and Drug Administration (FDA). The FDA first approved mifepristone, the primary drug used in medication abortion, in 2000; since that time, reliance on...
Today's Sponsors
Today's Sponsor